Please assess the completion status of the following clinical trial:

Trial Title: Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants 5 weeks of age (range: 35-41 days).~* Parents that consent for participation in the full length of the study.~* Parents that are able to understand and comply with planned study procedures.~Exclusion Criteria:~* Parents and infants who are unable to participate in the full length of the study.~* A diagnosis or suspicion of immunodeficiency disorder either in the infant or in an immediate family member.~* A diagnosis or suspicion of bleeding disorder that would contraindicate parenteral administration of fIPV or collection of blood by venipuncture.~* Evidence of a chronic medical condition identified by a study medical officer during physical exam.~* Infection or illness at the enrolment visit (i.e., 5 weeks of age) that a study medical officer judges would prevent the start of study activities at 6 weeks of age (i.e., blood collection and vaccination).~* Receipt of any polio vaccine (OPV or IPV/fIPV) before enrolment based upon documentation or parental recall.~* Known allergy/sensitivity or reaction to polio vaccine, or its contents.~* Infants from multiple births. Infants from multiple births will be excluded because the infant(s) who is/are not enrolled would likely receive OPV through routine immunization and transmit vaccine poliovirus to the enrolled infant.~* Infants from premature births (\<37 weeks of gestation).

- Gender: ALL
- Minimum Age: 35 Days
- Maximum Age: 41 Days
- Healthy Volunteers: t

Study Arms:
- mOPV1 + fIPV 6 weeks (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
- mOPV1 + fIPV 10 weeks (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
- mOPV1 only (Type: ACTIVE_COMPARATOR): mOPV1 administered at 6, 10, and 14 weeks.
- bOPV only (Type: ACTIVE_COMPARATOR): bOPV administered at 6, 10, and 14 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).